A research from European Society for blood and marrow transplantation (EBMT) reported that number of TNCs did not affect the survival endpoint after haplo-HSCT for 414 AML patients, while recipients of >4.96×106/kg CD34+ cells experienced reduced TRM and prolonged survival (29). The gene discussed is CD34; the disease is acute myeloid leukemia.